Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers

By JPN, Pharmaceutical, USA

 

Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers .

(NEW YORK and TOKYO – August 28, 2017) – Bristol-Myers Squibb Company (NYSE: BMY) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced a collaborative clinical trial to evaluate the combination of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) and Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 in HER2-expressing metastatic breast and urothelial (bladder) cancers. Media & Investors – Daiichi Sankyo

 

http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006696.html

More from tokioX :

  1. 💊Bristol-Myers Squibb Company, Opivo® (generic name: niborumab), approved as Fda as a treatment for hepatocellular cancer patients with treatment history with sorafenib  20170927
  2. MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies
  3. Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108
  4. Daiichi Sankyo Obtains Approval in Japan for Additional Indication and Dosage for Ovisot® for Injection in Diagnosis of Vasospastic Angina – Media & Investors
  5. 第一三共、経皮吸収癌疼痛治療剤 フェンタニルクエン酸塩貼付剤 後発医薬品の商業化に向け協業
  6. 小野薬品、オプジーボ®について、MSI-HまたはdMMRの転移性大腸がん治療薬としてFDA承認を取得 
  7. FDA、承認済み適応症に関して、ブリストル – マイヤーズスクイブのnivolumabの4週間投与申請を承認